^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    intraoperative cisplatin system (PRV211)

    i
    Other names: PRV211
    Associations

    News

    Trials
    Company:
    Privo Tech
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma (clinicaltrials.gov)
    P2/3, N=40, Recruiting, Privo Technologies | Trial completion date: Oct 2026 --> May 2027 | Trial primary completion date: Aug 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    intraoperative cisplatin system (PRV211)
    1year
    Safety and Efficacy Study of PRV111 and PRV211 in Subjects with Oral Squamous Cell Carcinoma (clinicaltrials.gov)
    P2/3, N=40, Recruiting, Privo Technologies | Phase classification: P1/2 --> P2/3
    Phase classification • Surgery
    |
    intraoperative cisplatin system (PRV211)
    1year
    Safety and Efficacy Study of PRV111 and PRV211 in Subjects with Oral Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Privo Technologies | Trial primary completion date: Jan 2025 --> Aug 2025
    Trial primary completion date • Surgery
    |
    intraoperative cisplatin system (PRV211)
    almost2years
    Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Privo Technologies | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    |
    intraoperative cisplatin system (PRV211)
    over2years
    Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, Privo Technologies
    New P1/2 trial • Surgery
    |
    cisplatin • intraoperative cisplatin system (PRV211)